Eton Pharmaceuticals, Inc. (ETON) is a Healthcare stock trading at $63.42 (as of 2026-08-21), with a market capitalization of $1.81B and a trailing P/E of 142.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals develops and commercializes specialty drugs for rare diseases, earning revenue from net product sales and royalty revenues, and also from licensing fees, divestiture-related licensing revenue, and launch milestone revenue.
Eton's profit is structurally driven by a small base of commercial product revenue (net product sales and royalties) combined with additional cash inflows from licensing arrangements and launch milestone payments, so changes in patient demand and milestone timing can swing results.
| Products | $0.0B |
| Licensing | $0.0B |
Business quality (Mixed): The company has positive gross and operating margins in the latest quarter, but the operating picture depends on rare-disease patient metrics and reimbursement, and it also shows meaningful reliance on licensing and on a small set of customers.
Valuation: At 650× earnings, ETON trades 3758% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $63.42 |
| Market Cap | $1.81B |
| P/E Ratio | 142.9 |
| EV / EBITDA | 87.0 |
| Price / Book | 38.91 |
| Price / Sales | 17.17 |
| FCF Yield | 1.9% |
| DCF Value (model) | $13.23 |
| DCF Upside vs Price | -79.1% |
| Revenue (TTM) | $79.95M |
| Net Margin | -5.8% |
| Revenue Growth (YoY) | 98.6% |
| EPS Growth (YoY) | -520.0% |
| FCF Growth (YoY) | -8.8% |
| Altman Z-Score | 15.16 (safe) |
| Piotroski F-Score | 5/9 (moderate) |
| Stock P/E | 142.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 557.3% |
| vs Industry | 731.8% |
| Top Institutional Holder | Opaleye Management Inc. ($70.58M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Sean E. Brynjelsen |
| Employees | 31 |
| Country | US |
| IPO Date | 2018-11-13 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.